Chronic interstitial nephritis Medical Services in China

Chronic interstitial nephritis (CIN) is a progressive, immune-mediated or toxic-inflammatory disorder characterized by persistent inflammation and fibrosis of the renal interstitium—the supportive tissue surrounding the tubules—leading to gradual loss of kidney function. Unlike acute interstitial nephritis, which often presents with abrupt onset and reversible injury, CIN evolves insidiously over months to years, frequently remaining asymptomatic until significant renal impairment (e.g., reduced GFR, elevated serum creatinine) or structural damage (e.g., tubular atrophy, interstitial fibrosis on biopsy) becomes evident. Pathogenesis involves dysregulated T-cell–mediated immune responses, chronic exposure to nephrotoxic agents (e.g., NSAIDs, proton pump inhibitors, aristolochic acid in herbal remedies), autoimmune conditions (e.g., Sjögren’s syndrome, sarcoidosis), or recurrent infections. Genetic susceptibility (e.g., HLA variants) and epigenetic modifications may amplify inflammatory signaling pathways such as NF-κB and TGF-β, driving fibroblast activation and extracellular matrix deposition. Epidemiologically, CIN accounts for approximately 10–15% of all cases of chronic kidney disease (CKD) requiring renal biopsy in tertiary nephrology centers; its true prevalence is likely underestimated due to underdiagnosis—many patients are labeled broadly as having 'CKD of unknown origin.' Incidence rises with age, peaking in adults aged 50–70 years, and shows modest male predominance (M:F ≈ 1.3:1). Key risk factors include long-term NSAID or PPI use (>6 months), traditional herbal medicine ingestion (especially in East Asia), uncontrolled autoimmune disease, chronic urinary obstruction, and recurrent pyelonephritis. Importantly, environmental exposures—such as occupational solvents or heavy metals—and metabolic comorbidities (e.g., hyperuricemia, diabetes) synergistically accelerate interstitial damage. Quality of life is profoundly impacted: fatigue, nocturia, and cognitive fog commonly precede overt renal failure; as disease advances, patients experience progressive anemia, fluid retention, electrolyte imbalances, and increased cardiovascular morbidity. Psychological burden—including anxiety about dialysis dependency and employment limitations—is high, particularly among working-age adults. Early diagnosis via kidney biopsy remains the gold standard, though non-invasive biomarkers (e.g., urinary β2-microglobulin, NGAL, KIM-1) and advanced MRI techniques (e.g., diffusion-weighted imaging) are emerging to support timely intervention. Without targeted management, CIN progresses to end-stage kidney disease (ESKD) in ~25–40% of cases within 5–10 years, necessitating renal replacement therapy.

Chronic interstitial nephritis (CIN) is a progressive, heterogeneous tubulointerstitial disorder characterized by persistent inflammation and fibrosis of the renal interstitium, leading to gradual loss of kidney function. Unlike glomerular diseases, CIN primarily affects the tubules and surrounding interstitium, often sparing the glomeruli until late stages. Etiologies include prolonged exposure to nephrotoxic agents (e.g., NSAIDs, proton pump inhibitors, aristolochic acid), autoimmune conditions (e.g., Sjögren’s syndrome, sarcoidosis, systemic lupus erythematosus), chronic infections (e.g., tuberculosis, pyelonephritis), metabolic disorders (e.g., hyperuricemia, hypercalcemia), and idiopathic causes. Diagnosis relies on clinical history, urinalysis (sterile pyuria, mild proteinuria <1 g/day, tubular dysfunction markers such as low-molecular-weight proteinuria or fractional excretion of sodium abnormalities), serum creatinine trends, imaging (often nonspecific but may show reduced kidney size or increased echogenicity), and—when indicated—renal biopsy demonstrating lymphoplasmacytic infiltration, tubular atrophy, and interstitial fibrosis without significant glomerular involvement.

Conservative management forms the cornerstone of CIN therapy and must be initiated promptly upon diagnosis. First and foremost, strict avoidance of all identifiable nephrotoxins is mandatory: NSAIDs, lithium, certain antibiotics (e.g., vancomycin in high-dose/long-term regimens), and herbal preparations containing aristolochic acid must be discontinued immediately. Patients with hyperuricemia require aggressive uric acid control via dietary modification (low-purine diet, hydration >2 L/day) and pharmacotherapy (allopurinol or febuxostat); similarly, hypercalcemia should be corrected through volume repletion, bisphosphonates if appropriate, and parathyroid hormone evaluation. Blood pressure must be tightly controlled to <130/80 mmHg using renin-angiotensin-aldosterone system (RAAS) inhibitors—preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)—which confer dual antihypertensive and antifibrotic benefits by reducing intraglomerular pressure and suppressing TGF-β–mediated fibrogenesis. Dietary counseling includes moderate protein restriction (0.6–0.8 g/kg/day of high-biological-value protein), sodium limitation (<2 g/day), and potassium/phosphate monitoring in advanced disease. Regular surveillance of eGFR, electrolytes, urinary biomarkers (e.g., N-acetyl-β-D-glucosaminidase, kidney injury molecule-1), and blood pressure is essential for timely intervention.

Pharmacologic treatment is etiology-specific and largely supportive. In autoimmune-associated CIN (e.g., tubulointerstitial nephritis and uveitis [TINU] syndrome or IgG4-related disease), corticosteroids remain first-line: prednisone 0.5–1 mg/kg/day for 4–6 weeks followed by slow taper over 3–6 months. For steroid-refractory or relapsing cases, immunosuppressants such as mycophenolate mofetil (target dose 1–1.5 g twice daily), azathioprine (2–2.5 mg/kg/day), or rituximab (375 mg/m² weekly × 4 or 1000 mg × 2 doses two weeks apart) may be employed. In sarcoidosis-related CIN, corticosteroids are also primary; methotrexate or TNF-α inhibitors (e.g., infliximab) are considered in refractory granulomatous inflammation. For drug-induced CIN, steroids are generally not recommended unless biopsy confirms severe active inflammation with rapid functional decline—evidence supporting their use remains limited and controversial. Adjunctive therapies under investigation include bardoxolone methyl (Nrf2 activator, though withdrawn from Phase III due to cardiovascular safety signals) and pirfenidone (antifibrotic agent showing promise in preclinical models). Importantly, no FDA- or EMA-approved disease-modifying drugs exist specifically for CIN; thus, pharmacotherapy remains individualized and evidence-informed rather than guideline-mandated.

Surgical intervention has no routine role in CIN management. However, in select scenarios, procedures may be indicated: ureteral stenting or percutaneous nephrostomy is performed for obstructive uropathy contributing to interstitial injury; nephrectomy may be considered in unilateral, severely damaged kidneys causing intractable hypertension or recurrent infection—though this is exceedingly rare. Renal transplantation is the definitive treatment for end-stage kidney disease (ESKD) secondary to CIN. Graft survival rates are comparable to other non-immune-mediated ESKD etiologies, provided the underlying cause (e.g., uncontrolled sarcoidosis or ongoing toxin exposure) is rigorously excluded pre-transplant. Post-transplant recurrence of CIN is uncommon but reported in IgG4-related disease and Sjögren’s syndrome; therefore, close rheumatologic follow-up and maintenance immunosuppression are critical.

China offers distinct advantages in the multidisciplinary management of CIN. First, the national Chronic Kidney Disease (CKD) Prevention and Control Program enables early detection through community-based screening (serum creatinine, urine dipstick, ACR) integrated into primary care, facilitating timely referral to nephrology centers. Second, China’s robust traditional Chinese medicine (TCM) infrastructure complements Western approaches: evidence-based TCM formulas such as Huangkui capsule (Abelmoschus manihot extract) have demonstrated antiproteinuric and anti-inflammatory effects in randomized trials involving tubulointerstitial injury, while acupuncture protocols targeting kidney meridians show adjunctive benefit in symptom control (e.g., fatigue, nocturia). Third, China leads globally in real-world data generation via large-scale electronic health record systems (e.g., the China Kidney Disease Network), enabling rapid identification of epidemiologic patterns—such as the high prevalence of aristolochic acid nephropathy in southern provinces—and informing region-specific prevention strategies. Finally, cost-effective access to generic immunosuppressants and biosimilar biologics significantly improves long-term adherence, particularly among rural and elderly populations.

Recovery and long-term prognosis depend heavily on early diagnosis, etiologic control, and sustained adherence to conservative measures. Patients should undergo quarterly nephrology visits with eGFR trend analysis, annual renal ultrasound, and periodic assessment of tubular function (e.g., urine β2-microglobulin, serum bicarbonate). Lifestyle modifications are non-negotiable: smoking cessation (smoking accelerates interstitial fibrosis), strict glycemic control in diabetic patients (HbA1c <7%), and avoidance of contrast media unless absolutely necessary (with pre-hydration and iso-osmolar agents). Psychological support is integral—chronic kidney disease correlates strongly with depression and anxiety—thus integrating mental health professionals into nephrology care teams is increasingly standard in tier-3 hospitals. Patient education empowers self-monitoring: home blood pressure logs, symptom diaries (e.g., edema, dyspnea), and medication reconciliation tools reduce hospitalizations. With optimal management, many patients stabilize eGFR decline to <2 mL/min/year, preserving native kidney function for decades. Ultimately, CIN demands a proactive, personalized, and perpetually vigilant approach—where prevention, precision, and patient partnership converge to mitigate irreversible fibrosis and preserve quality of life.